The goal of this pilot clinical trial is to determine the effectiveness of Tirzepatide in patients with persistent obesity (BMI > 30) 12 months after bariatric surgery (Roux-en-Y Gastric Bypass). The investigators also aim to determine the frequency of side effects with Tirzepatide in this patient population. Patients who take tirzepatide 12 months after bariatric surgery will be compared to patients who receive a placebo.

Start Date01 Oct 2024

Sponsor / Collaborator

Vanderbilt University Medical Center

NCT06073184 / Not yet recruitingPhase 2

Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium (WE-FiERCE)

The incidence of endometrial cancer is increasing at an alarming rate. This trend parallels the rising rate of obesity, the most significant risk factor for endometrial cancer. Young women with obesity and endometrial cancer or atypical hyperplasia who want to maintain their fertility are treated with progestin therapy, such as progestin intra-uterine device (pIUD), which is associated with a mediocre response rate and high recurrence rate, and does not address the underlying cause, obesity. Therefore, the investigators want to assess whether the addition of a weight-loss drug to pIUD will improve their oncologic, reproductive and metabolic outcomes.

Start Date01 Sep 2024

Sponsor / Collaborator

University Health Network

NCT06246799 / Not yet recruitingPhase 3IIT

Comparative Effectiveness of Two Initial Combination Therapies in Patients With New Onset Diabetes

The goal of this randomized, open labelled clinical trial is to examine the efficacy, durability, and mechanism of HbA1c reduction produced by the combination of pioglitazone plus tirzepatide versus metformin plus sitagliptin in recently diagnosed type 2 diabetes mellitus patients.
The main question[s] it aims to answer are:
How effective is the combination of pioglitazone plus tirzepatide in managing blood sugar levels in people with type 2 diabetes? How does this combination compare to the use of metformin plus sitagliptin in controlling blood sugar levels? Participants will receive Pioglitazone beginning at 15 mg daily and ending 45 mg daily. (15mg month 1, 30mg month 2 and 45mg at month 3 onwards)

Start Date01 Jul 2024

Sponsor / Collaborator

University of Texas Health Science Center At San Antonio

[+1]

100 Clinical Results associated with Tirzepatide

100 Translational Medicine associated with Tirzepatide

100 Patents (Medical) associated with Tirzepatide

330

Literatures (Medical) associated with Tirzepatide

01 Mar 2024·Peptides

Recent advances in peptide-based therapies for obesity and type 2 diabetes

Article

Author: Flatt, Peter R ; Conlon, J Michael ; Bailey, Clifford J

Options for the treatment of type 2 diabetes mellitus (T2DM) and obesity have recently been expanded by the results of several large clinical trials with incretin-based peptide therapies. Most of these studies have been conducted with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, which is available as a once weekly subcutaneous injection and once daily tablet, and the once weekly injected dual agonist tirzepatide, which interacts with receptors for GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). In individuals with T2DM these therapies have achieved reductions of glycated haemoglobin (HbA1c) by > 2% and lowered body weight by > 10%. In some studies, these agents tested in non-diabetic, obese individuals at much higher doses have lowered body weight by > 15%. Emerging evidence suggests these agents can also offer cardio-protective and potentially reno-protective effects. Other incretin-based peptide therapies in early clinical development, notably a triple GLP-1/GIP/glucagon receptor agonist (retatrutide) and a combination of semaglutide with the amylin analogue cagrilintide (CagriSema), have shown strong efficacy. Although incretin therapies can incur adverse gastrointestinal effects these are for most patients mild-to-moderate and transient but result in cessation of treatment in some cases. Thus, the efficacy of new incretin-based peptide therapies is enhancing the opportunity to control body weight and blood glucose and improve the treatment of T2DM and obesity.

22 Jan 2024·Expert opinion on pharmacotherapy

Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?

Review

Author: Mondoh, Alvin ; Le Roux, Carel

INTRODUCTION:

Obesity, marked by abnormal fat accumulation, poses significant health risks, necessitating effective therapeutic interventions. The focus of this review is to elucidate the importance of glucagon-like peptide 1 (GLP-1) receptor-binding medications in addressing obesity-related health deteriorations.

AREAS COVERED:

Exploring the mechanisms, efficacy, and safety profiles, this review comprehensively assesses medications selectively or non-selectively binding the GLP-1 receptor for obesity treatment. A meticulous analysis of phase 2 and phase 3 data positions retatrutide, CagriSema, survudotide, tirzepatide, semaglutide, and liraglutide in order of effectiveness. While showcasing their efficacy and safety, the review acknowledges the ongoing phase 3 studies, highlighting the need for further exploration of contraindications, dosage, and potential adverse effects to inform personalized treatment decisions.

EXPERT OPINION:

The ongoing anticipation of long-term benefits, particularly sustained weight loss and cardiovascular outcomes, underscores the significance of future treatment algorithms for addressing the disease of obesity.

International journal of obesity (2005)

What is the pipeline for future medications for obesity?

Review

Author: Melson, Eka ; Papamargaritis, Dimitris ; Ashraf, Uzma ; Davies, Melanie J

Abstract:

Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe and effective entero-pancreatic hormone-based treatments for obesity such as glucagon-like peptide-1 (GLP-1) receptor agonists (RA). Semaglutide 2.4 mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 15–17% mean weight loss (WL) with evidence of cardioprotection. Oral GLP-1 RA are also under development and early data shows similar WL efficacy to semaglutide 2.4 mg. Looking to the next generation of obesity treatments, combinations of GLP-1 with other entero-pancreatic hormones with complementary actions and/or synergistic potential (such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) are under investigation to enhance the WL and cardiometabolic benefits of GLP-1 RA. Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials. Other combinations of entero-pancreatic hormones including cagrisema (GLP-1/amylin RA) and the triple agonist retatrutide (GLP-1/GIP/glucagon RA) have also progressed to phase 3 trials as obesity treatments and early data suggests that may lead to even greater WL than tirzepatide. Additionally, agents with different mechanisms of action to entero-pancreatic hormones (e.g. bimagrumab) may improve the body composition during WL and are in early phase clinical trials. We are in a new era for obesity pharmacotherapy where combinations of entero-pancreatic hormones approach the WL achieved with bariatric surgery. In this review, we present the efficacy and safety data for the pipeline of obesity pharmacotherapies with a focus on entero-pancreatic hormone-based treatments and we consider the clinical implications and challenges that the new era in obesity management may bring.

666

News (Medical) associated with Tirzepatide

01 Jul 2024

·www.prnewswire.com

Introducing SHOWW, the Only Telemedicine Company in the Industry Offering a FDA-Regulated 503B Pharmacy Compounded Semaglutide

MIAMI, July 1, 2024 /PRNewswire/ -- Companies can tell their prospective customers anything, but a recently launched business prefers guaranteed results. SHOWW is a weight loss telemedicine brand offering compounded semaglutide, which is the active ingredient in medications like Wegovy® and Ozempic®. SHOWW sets itself apart from other similar companies in the industry with its ultra-high quality FDA-Regulated 503B Pharmacy Compounded Semaglutide. Continue Reading SHOWW your best self. Semaglutide is an injectable medication initially prescribed as a diabetes treatment. The United States Food and Drug Administration approved it as a medical treatment for weight loss in 2021, and it has taken the world by storm since then. Recent research from the University of California, Los Angeles, shows semaglutide can be an effective way to help support weight loss by curbing appetite while reducing the risk of cancer, diabetes, and heart disease in overweight people. Weight loss medications featuring semaglutide have been prominent in the medical community in recent years, but not all providers are the same. Many brand-name semaglutide products can cost over $1,200 monthly. At SHOWW, customers enjoy the same level of quality and safety for a quarter of the price. The company uses clear pricing and transparent processes, with no hidden fees or manipulative tactics. Standing Out in the Crowd Telemedicine is an emerging industry, and many people may not know how simple it can be to speak with a doctor, get a prescription, and order recurring medication delivery from the comfort of home. At SHOWW, there are no appointments or wait times, and clients can receive their semaglutide in as little as four days. SHOWW is the only semaglutide provider that employs a team of licensed doctors specializing in weight loss exclusively to prescribe medication and monitor patients' progress. These physicians do not offer any other services outside personalized weight loss solutions. The in-house team ensures clients aren't forced to endure long wait times to receive a prescription and treatment while preventing crossed wires or communication delays. Safe and Reliable Solutions As the usage of semaglutide grows, it becomes increasingly important for consumers to ensure they receive safe, accurate prescription medications. With SHOWW, clients experience premium telemedicine solutions and a reliable, personalized approach to their healthcare. SHOWW's products are manufactured in a $250 million 503B compounding pharmacy. Unlike 503A facilities, every process at SHOWW must be validated. All medications are submitted for testing prior to being released for sale, ensuring every prescription leaving the facility is of consistent quality and meets all regulatory guidelines. This testing allows 503B compounding pharmacies to guarantee they produce the highest-quality products fit for use in doctor's offices, clinics, and hospitals. The popularity of semaglutide as a weight loss medication has been so widespread that many areas have experienced shortages. SHOWW's 503B compounding pharmacy manufactures its products independently, so its productivity isn't dependent on external supply chains, and customers will not experience shortages. Delivering Guaranteed Results The internet is rife with scam companies out to take a customer's money without making a timely delivery of the product as described. SHOWW works to offer clients as much transparency, security, and convenience as possible while reliably delivering high-quality medication. Clients enjoy fast, free shipping at SHOWW. All orders ship within 24 hours through FedEx or a two-day UPS courier, which means customers receive their medication less than four days after ordering it. Unlike many online providers, SHOWW always has semaglutide in stock, and customers never have to worry about inconvenient delays or issues refilling their medication. According to a litany of customer complaints filed with the Better Business Bureau, many telemedicine providers rely on automated customer support. By contrast, SHOWW offers its clients 24/7 assistance via phone, email, SMS, or live chat. The customer's experience and satisfaction are a priority for SHOWW, and it works to ensure clients can always find answers to their questions. The team is entirely based in the United States, and live representatives are available from 9 a.m. to 6 p.m. EDT daily. All inquiries are answered within 24 hours. Medicine-Assisted Weight Management in Four Steps Getting started with SHOWW is a simple process. Start by completing an online application. In five minutes, clients learn whether SHOWW can help support their weight loss goals. If they are a good match, a licensed doctor will review their information and decide whether semaglutide is an appropriate treatment. "Online consultations at SHOWW are typically free," representatives said. "You'll only pay for the prescription if you qualify after your medical consultation." Once a doctor prescribes the medication, the order is passed on to SHOWW's 503B compounding pharmacy partner and delivered in under four days. As treatments continue, patients monitor their progress and measure it against their goals during monthly doctor check-ins. "We aim to ensure every patient understands their treatment and achieves the best results," SHOWW founders said. "Our support team and physicians are available for free, unlimited follow-ups." In addition to semaglutide, SHOWW offers GLP-1 medications like tirzepatide, which is the active ingredient in similar products like Zepbound™ and Mounjaro®. The company's team of qualified weight loss specialists will determine the most appropriate medications for an individual client's treatment goals, which may include additional drugs like metformin. Semaglutide prescription is not guaranteed for every client and is dependent upon physician approval. Semaglutide treatment is generally not recommended for individuals with a history of medullary thyroid cancer, gallbladder disease, pancreatitis, or multiple endocrine neoplasia syndrome type 2. "Your health journey is unique, and so is our approach to your care," SHOWW founders said. "Rest assured, your treatment plan will be as unique as you are." Affordable and Accessible While SHOWW does not currently accept insurance coverage for its services, the products it provides can often be less expensive than many co-payments. Offering free virtual consultations further reduces the costs and makes medication-assisted weight loss affordable and accessible to ideal candidates. With SHOWW, affordable telemedicine weight loss solutions are available to all qualified patients in the United States. Not only do customers reliably receive their semaglutide medication on time, but they can rest assured that refill prescriptions will also arrive on time and they'll never be left in dark due to shortages or backlogs. Welcome to the SHOWW When it comes to online solutions for weight loss, one telemedicine brand prefers to SHOWW rather than tell. Visit the SHOWW website to learn more about the telemedicine brand or to schedule a free weight loss consultation. It takes less than five minutes to complete the initial online application and discover whether semaglutide might be an appropriate treatment option. Current and prospective customers may also contact SHOWW at (888) 413-7469 or email [email protected]. The brand maintains an online presence on Facebook and Instagram for those who wish to contact SHOWW for social media purposes. SOURCE SHOWW LLC

Drug Approval

28 Jun 2024

·www.echemi.com

Eli Lilly's Zepbound (Tizepatide) Demonstrates Promising Results in Treating Obesity and Obstructive Sleep Apnea

In the era of rapid advancement in medical technology, obesity and its related complications are becoming a global public health challenge. Recently, Eli Lilly has made significant progress in obesity treatment, which is the result of the positive results of its GIP/GLP-1 weight-loss drug Zepbound (also known as tizepatide) in the SURMOUNT-OSA 3-phase study. Earlier this week, Eli Lilly announced the detailed study data, which targeted obese patients with obstructive sleep apnea (OSA). What is exciting is that the study results show that both patients receiving positive airway pressure (PAP) treatment and those not receiving treatment saw significant improvements in all major and secondary treatment endpoints with 10mg and 15mg doses of Zepbound. This discovery not only brings good news to obese patients, but also further solidifies Eli Lilly's leading position in the field of diabetes and obesity treatment. The research team published these data in the New England Journal of Medicine and fully presented the research results at the 84th Annual Scientific Meeting of the American Diabetes Association in Orlando, Florida on Friday. This milestone achievement has attracted widespread attention from the industry. Zepbound, as a pioneering drug from Eli Lilly, was initially recognized in the obesity treatment field in November last year. This drug can not only be used at a higher dose to treat obesity, but also at a lower dose to treat type 2 diabetes, and is called Mounjaro. In certain countries outside the United States, this drug has been widely used in the fields of weight loss and diabetes treatment and is simply referred to as Mounjaro. In the SURMOUNT-OSA 3 phase study, Zepbound demonstrated excellent efficacy. The study data showed that the average AHI (apnea-hypopnea index) was reduced by 62.8% in patients receiving Zepbound treatment. AHI is an important indicator of the severity of OSA, determined by tracking sleep-related breathing problems per hour of sleep. Compared with the placebo group, this result means that the number of events that obstruct or limit the patient's airflow per hour of sleep decreased by about 30, greatly improving the patient's sleep quality and quality of life. Moreover, the study found that 43% of untreated patients and 51.5% of patients using PAP machines reached the remission standard after receiving the highest dose of Zepbound treatment. Eli Lilly defines remission as having an AHI of fewer than 5 events per hour or an AHI of 5 to 14 events per hour with an Epworth Sleepiness Scale (ESS) score of 10. The ESS is a questionnaire used to measure daytime excessive sleepiness and is of great importance in evaluating the symptoms of OSA patients. Dr. Jeff Emmick, Senior Vice President of Product Development at Eli Lilly, stated in a statement that approximately 80 million Americans suffer from obstructive sleep apnea (OSA), a chronic disease that has a significant impact on their quality of life. However, there are currently no specific drug treatments that directly address the underlying causes of the disease. The successful development of Zepbound provides new treatment options for patients and has the potential to become an important drug in the OSA treatment field in the future. In addition to its significant efficacy in OSA patients, Zepbound also shows great potential in treating other obesity-related conditions. For example, in another study, Zepbound helped more than half of the metabolic dysregulation and fatty liver disease (MASH) patients reduce their stage of fibrosis by at least one stage, without any worsening of the condition. This finding further demonstrates the broad application prospects of Zepbound in the treatment of obesity and its complications. Eli Lilly is also testing the effectiveness of tesiprotamine in preserving ejection fraction in heart failure patients. This research has the potential to bring new hope to heart failure patients and further expand the application scope of tesiprotamine in cardiovascular diseases. Despite some analysts believing that Tezepelumab will ultimately lead ahead of Novo Nordisk's diabetes and obesity competitors Ozempic and Wegovy (both of which are based on the GLP-1 molecule semaglutide), Eli Lilly is currently actively catching up to its Danish rival. In March this year, Novo Nordisk's Wegovy became the first FDA-approved weight loss drug, able to reduce the risk of cardiovascular death, heart attacks, and strokes in obese or overweight adults with cardiovascular disease. However, with Zepbound's positive progress in multiple areas, Lilly is expected to achieve a turnaround in the future. In terms of finance, Mounjaro and Zepbound have brought considerable revenue to Eli Lilly. In 2023, Mounjaro brought $5.16 billion in revenue for Eli Lilly in type 2 diabetes, while Zepbound brought $175.8 million in revenue. Although there is still a gap compared to Novo Nordisk's Ozempic and Wegovy (Ozempic's sales for the same period were approximately $13.8 billion, and Wegovy contributed about $4.5 billion to Novo Nordisk's 2023 sales), the potential and market prospects of Zepbound are worth looking forward to. In summary, Zepbound's positive progress in obesity treatment has brought new hope to obese patients. As research progresses and clinical applications expand, Zepbound is expected to become one of the important drugs for treating obesity and its related complications in the future.

Clinical ResultPhase 3Drug Approval

27 Jun 2024

·www.biospace.com

Amide Technologies Appoints Co-Founder and MIT Chemistry Professor as CEO

Dr. Brad Pentelute to Lead Amide’s Revolutionary Peptide Manufacturing Platform CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amide Technologies, a leading biotech company specializing in the synthesis of complex peptides, announced today the appointment of Dr. Brad Pentelute as its new CEO. Dr. Pentelute, who co-founded Amide while heading the Pentelute Lab at MIT's Department of Chemistry, will succeed interim CEO Dr. Mark Simon. With over 12 years of experience as a Professor of Chemistry at MIT, Dr. Pentelute brings a wealth of expertise from his previous roles as a Postdoctoral Fellow at Harvard Medical School, a Senior Scientist at Ethos Pharmaceuticals, and a graduate student at the University of Chicago. During his sabbatical from MIT, Dr. Pentelute will focus on scaling Amide’s operations, enhancing product offerings, leveraging AI capabilities, and driving the company towards greater profitability. This press release features multimedia. View the full release here: Dr. Brad Pentelute (Photo: Business Wire) “With the rising prevalence of cancers and metabolic disorders, coupled with increasing investments in novel drug research and development, the demand for peptide therapeutics is surging. However, the challenges of stringent regulatory requirements and high development costs often hinder peptide-based drug discovery,” stated Dr. Pentelute. “Amide’s advanced synthesis capabilities enable biopharma companies to rapidly develop and iterate complex peptides, unlocking a broader spectrum of therapeutic possibilities. I am excited to lead Amide’s next phase of growth and ensure that peptide sourcing accelerates, rather than impedes, drug discovery. Our goal is to produce thousands of peptides in short timeframes to meet global demand.” Amide Technologies is at the intersection of robotics, chemistry, and AI, driving major advancements in peptide manufacturing. The company's cutting-edge platform uses robotic automation and AI to perform rapid flow peptide synthesis, enabling high-throughput production and unparalleled precision. This fusion of technology and science is key to Amide's ability to scale its operations and meet the growing needs of the biopharma industry. The peptide therapeutics market, projected to reach $82.6 billion by 2032, includes well-known drugs for conditions such as Type II diabetes (Mounjaro, Ozempic, Trulicity, Victoza), osteoporosis (Forteo), and cancer (Lupron, Zoladex). Amide’s novel manufacturing platform synthesizes otherwise inaccessible peptides at unprecedented speeds. With $16.5 million in funding to date, Amide supports pharmaceutical and peptide therapeutics companies by providing: Complex synthesis of peptides with 120+ amino acids, previously unattainable. Rapid delivery of peptides within just four days, maintaining a 99% on-time delivery rate. Expansive therapeutic potential through access to large and unconventional compounds. “Peptides are crucial for new drug discovery, yet traditional sourcing methods limit the exploration of diverse amino acid chains. Amide’s innovations in fast and complex peptide synthesis are groundbreaking, and with Dr. Pentelute’s leadership, the company is poised to significantly advance peptide-based drug development,” said Reed Sturtevant, General Partner at The Engine Ventures and Amide Board Member. Dr. Pentelute has made significant research contributions, leading to the invention of new chemistry and AI methods to modify natural proteins for enhanced therapeutic properties. Amide holds exclusive licensing rights to these technologies through MIT patents. Dr. Pentelute’s accolades include the Sloan Research Fellowship in Chemistry, Eli Lilly Award in Biological Chemistry, Amgen Young Investigator Award, and Novartis Early Career Award in Organic Chemistry. About Amide Technologies Amide Technologies is a biotech startup offering on-demand complex peptide manufacturing at unprecedented speed. Developed at MIT, Amide’s novel platform bridges the gap between traditional solid-phase peptide synthesis and biological expression, empowering scientists at the forefront of peptide drug design. To learn more about Amide, visit amidetech.com.

Executive Change

100 Deals associated with Tirzepatide

External Link

KEGG	Wiki	ATC	Drug Bank
D11360	-	-	DB15171

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	US	Eli Lilly & Co.	08 Nov 2023
Overweight	US	Eli Lilly & Co.	08 Nov 2023
Diabetes Mellitus, Type 2	US	Eli Lilly & Co.	13 May 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Sleep Apnea, Obstructive	NDA/BLA	US	Eli Lilly & Co.	21 Jun 2024
Weight Gain	Phase 3	US	Eli Lilly & Co.	01 Jun 2024
Weight Gain	Phase 3	AR	Eli Lilly & Co.	01 Jun 2024
Weight Gain	Phase 3	AU	Eli Lilly & Co.	01 Jun 2024
Weight Gain	Phase 3	CA	Eli Lilly & Co.	01 Jun 2024
Weight Gain	Phase 3	FR	Eli Lilly & Co.	01 Jun 2024
Weight Gain	Phase 3	DE	Eli Lilly & Co.	01 Jun 2024
Weight Gain	Phase 3	IL	Eli Lilly & Co.	01 Jun 2024
Weight Gain	Phase 3	MX	Eli Lilly & Co.	01 Jun 2024
Weight Gain	Phase 3	PR	Eli Lilly & Co.	01 Jun 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04657003 (SURMOUNT-2, ADA2024) Manual	Phase 3	Diabetes Mellitus, Type 2 \| Obesity	-	Tirzepatide	tbeekqwerk(bvbyratbmb) = hgsyomlrou jjhnyrihyg (jmhhneurkn )	Positive	21 Jun 2024
				Placebo	-
NCT04166773 (SYNERGY-NASH, Biospace \| EASL2024) Manual	Phase 2	Nonalcoholic Steatohepatitis	157	Tirzepatide 5mg	blopygzzzj(pjragoumom) = ttvjocfgyc uplkgpdrry (zhojtrbsaa ) View more	Positive	05 Jun 2024
				Tirzepatide 10mg	blopygzzzj(pjragoumom) = dymjzwmnjc uplkgpdrry (zhojtrbsaa ) View more
NCT04660643 (SURMOUNT-4, CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Obesity	783	Placebo (Placebo)	zgbcyzubzt(ogpjpsfenp) = sevyewzxqd ypdnwllehu (mkrldfncrc, ssruayacjr - hrzcgqpdzv) View more	-	22 May 2024
				Tirzepatide (Tirzepatide MTD)	zgbcyzubzt(ogpjpsfenp) = dihiyrmbaf ypdnwllehu (mkrldfncrc, hinonmrcgg - sskkluhrfi) View more
NCT04311411 (CTgov)	Phase 1	Obesity	114	Placebo (Placebo)	zrawqeuqax(cvdjfolege) = kgltotwryr lhbijdtvxc (ybxkzvoans, vgotjshwce - kbbkyrtppq) View more	-	22 May 2024
				Tirzepatide (Tirzepatide)	zrawqeuqax(cvdjfolege) = fpxwwzlmbs lhbijdtvxc (ybxkzvoans, izhfrddpza - rwlncgbiid) View more
NCT04050553 (CTgov)	Phase 1	Diabetes Mellitus, Type 2 \| Hypoglycemia	42	Placebo	uxgznfmnki(kwdkwmdfwa) = fbrvzpyyzj thsvrayzns (fjyjlyowxn, iqzliqkxdd - jduxnickvn) View more	-	20 May 2024
NCT04657016 (CTgov)	Phase 3	Obesity \| Diabetes Mellitus, Type 2	579	Placebo (Placebo)	hihbciextg(wqfeyjnjrj) = dqoxcutjih ikkeujukzd (icjdrflogm, wknlkhital - ussvgtccju) View more	-	16 May 2024
				Tirzepatide (Tirzepatide)	hihbciextg(wqfeyjnjrj) = aauvaguxus ikkeujukzd (icjdrflogm, bsrtzvsndi - sorzgaujei) View more
NCT05412004 (SURMOUNT-OSA, Corporate Publications) Manual	Phase 3	Sleep Apnea, Obstructive \| Obesity	469	Tirzepatide (Participants Not on PAP Therapy)	nmxkarbbho(wlugdwjxzg) = dkvrnebouq oefpoakusu (qozuzqfhxv ) Met View more	Positive	17 Apr 2024
				Tirzepatide (Participants Used PAP Therapy)	nmxkarbbho(wlugdwjxzg) = eptuxtvjem oefpoakusu (qozuzqfhxv ) Met View more
NCT04657003 (SURMOUNT-2, CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Obesity	938	Placebo (Placebo)	ykqfhtrtpe(mbiouepeiw) = qaxymqziao gllwfnqqmx (bblxekehrm, zqhdkjzygi - kersebyeyg) View more	-	08 Apr 2024
				Tirzepatide (15 mg Tirzepatide)	ykqfhtrtpe(mbiouepeiw) = goycevdwrt gllwfnqqmx (bblxekehrm, cebymxzzdh - wphowmigjx) View more
NCT04081337 (CTgov)	Phase 1	Obesity	55	Placebo	emcpqjnvrs(yirqxuoebl) = dnewktfodp aldrvvrjto (xoxlzsxizt, qwtwpbngqn - rbfsfvyzqs) View more	-	08 Feb 2024
NCT04184622 (SURMOUNT-1, Literature) Manual	Phase 3	Obesity	600	Tirzepatide 5 mg	lvszwihkde(iexpgadwcj) = lddfgwpsmx ozvqitisix (zdntuquaue, - 10.0 - - 4.7) View more	Positive	05 Feb 2024
				Tirzepatide 10 mg	lvszwihkde(iexpgadwcj) = jruwnzksdw ozvqitisix (zdntuquaue, - 13.2 - - 8.0) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis